Monaco Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Monaco Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$1.01M	–	108
2025 Q3	$1.01M	Sell	50,000 -50,000	-50%	-$878K	0.06%	64
2025 Q2	$1.68M	Sell	100,000 -125,000	-56%	-$2.02M	0.29%	50
2025 Q1	$3.46M	Buy	+225,000	New	+$4.02M	0.71%	21
2024 Q3	–	Sell	-475,000	Closed	-$7.72M	–	81
2024 Q2	$7.72M	Sell	475,000 -889,121	-65%	-$13.7M	1.23%	14
2024 Q1	$19.2M	Sell	1,364,121 -3,179	-0.2%	-$40.1K	5.76%	5
2023 Q4	$14.3M	Sell	1,367,300 -157,700	-10%	-$1.47M	4.2%	6
2023 Q3	$15.6M	Buy	1,525,000 +590,587	+63%	+$5.5M	4.61%	6
2023 Q2	$7.04M	Buy	+934,413	New	+$7.58M	1.96%	15
2023 Q1	–	Sell	-75,000	Closed	-$684K	–	83
2022 Q4	$684K	Sell	75,000 -59,000	-44%	-$515K	0.21%	58
2022 Q3	$1.08M	Buy	+134,000	New	+$1.18M	0.41%	42

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Monaco Asset Management's TEVA Position: Q4 2025 in Review

Monaco Asset Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 50,000 shares — an estimated $1.01M sold.

Monaco Asset Management first reported a position in TEVA in Q3 2022 and held it in 10 quarters. The position peaked at $19.2M in Q1 2024. 629 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

Monaco Asset Management reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Monaco Asset Management sold 50,000 Teva Pharmaceuticals shares in Q4 2025, an estimated $1.01M.
Monaco Asset Management first reported a position in Teva Pharmaceuticals in Q3 2022 and held it in 10 quarters.
Monaco Asset Management's Teva Pharmaceuticals position peaked at $19.2M in Q1 2024.
629 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Monaco Asset Management's 13F filing for Q4 2025, filed 10 Feb 2026.